Skip to main content
Top
Published in: Journal of Clinical Immunology 2/2017

01-02-2017 | Original Article

Increased Incidence of Fatigue in Patients with Primary Immunodeficiency Disorders: Prevalence and Associations Within the US Immunodeficiency Network Registry

Authors: Joud Hajjar, Danielle Guffey, Charles G. Minard, Jordan S. Orange

Published in: Journal of Clinical Immunology | Issue 2/2017

Login to get access

Abstract

Introduction

Patients with primary immunodeficiency (PID) often report fatigue, yet this symptom has not been studied in PID. Fatigue affects 6–7.5% of healthy adults. The goal of this study is to estimate the prevalence of fatigue in patients with PID and investigate its associated factors.

Methods

We analyzed 2537 PID patients registered in USIDNET to determine responses to the field “fatigue” in the core registry form. Demographics, immune phenotypes, and comorbid conditions were compared between fatigued and non-fatigued patients to identify relevant associations and potential drivers. A focused analysis was performed for patients with predominantly antibody deficiency disorders (PADs).

Results

Fatigue was reported in 25.9% (95% CI 23.7–28.3) of PAD patients, compared to 6.4% (95% CI 4.9–8.2) of non-PAD. Patients with common variable immunodeficiency (CVID) had the highest prevalence of fatigue (p < 0.001) among all PID diagnoses. Other factors that were associated with a higher rate of fatigue among PAD patients included female sex, higher BMI, depression, bronchiectasis, and autoimmunity. Additionally, fatigued PAD patients had lower absolute lymphocyte, CD3, CD4, and CD8 counts compared to non-fatigued patients.

Conclusion

Our findings suggest that fatigue is overrepresented in PAD patients. Prospective studies to estimate prevalence, risk factors, and fatigue etiology in PID are warranted, so therapeutic interventions can be considered.
Literature
1.
go back to reference Bonilla FA, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1186–205. e78CrossRefPubMed Bonilla FA, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1186–205. e78CrossRefPubMed
3.
go back to reference Bousfiha AA, et al. Primary immunodeficiency diseases worldwide: more common than generally thought. J Clin Immunol. 2013;33(1):1–7.CrossRefPubMed Bousfiha AA, et al. Primary immunodeficiency diseases worldwide: more common than generally thought. J Clin Immunol. 2013;33(1):1–7.CrossRefPubMed
4.
go back to reference Kobrynski L, Powell RW, Bowen S. Prevalence and morbidity of primary immunodeficiency diseases, United States 2001-2007. J Clin Immunol. 2014;34(8):954–61.CrossRefPubMedPubMedCentral Kobrynski L, Powell RW, Bowen S. Prevalence and morbidity of primary immunodeficiency diseases, United States 2001-2007. J Clin Immunol. 2014;34(8):954–61.CrossRefPubMedPubMedCentral
5.
go back to reference Busse PJ, Razvi S, Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol. 2002;109(6):1001–4.CrossRefPubMed Busse PJ, Razvi S, Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol. 2002;109(6):1001–4.CrossRefPubMed
6.
go back to reference Orange JS, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006;117(4 Suppl):S525–53.CrossRefPubMed Orange JS, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006;117(4 Suppl):S525–53.CrossRefPubMed
7.
go back to reference Roifman CM, et al. Benefit of intravenous IgG replacement in hypogammaglobulinemic patients with chronic sinopulmonary disease. Am J Med. 1985;79(2):171–4.CrossRefPubMed Roifman CM, et al. Benefit of intravenous IgG replacement in hypogammaglobulinemic patients with chronic sinopulmonary disease. Am J Med. 1985;79(2):171–4.CrossRefPubMed
8.
go back to reference Jiang F, Torgerson TR, Ayars AG. Health-related quality of life in patients with primary immunodeficiency disease. Allergy Asthma Clin Immunol. 2015;11:27.CrossRefPubMedPubMedCentral Jiang F, Torgerson TR, Ayars AG. Health-related quality of life in patients with primary immunodeficiency disease. Allergy Asthma Clin Immunol. 2015;11:27.CrossRefPubMedPubMedCentral
9.
go back to reference Efficace F, et al. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia. 2013;27(7):1511–9.CrossRefPubMed Efficace F, et al. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia. 2013;27(7):1511–9.CrossRefPubMed
10.
go back to reference Efficace F, et al. Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. Lancet Oncol. 2015;16(15):1506–14.CrossRefPubMed Efficace F, et al. Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. Lancet Oncol. 2015;16(15):1506–14.CrossRefPubMed
11.
go back to reference Gripp S, et al. Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression. J Clin Oncol. 2007;25(22):3313–20.CrossRefPubMed Gripp S, et al. Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression. J Clin Oncol. 2007;25(22):3313–20.CrossRefPubMed
13.
go back to reference Moreh E, Jacobs JM, Stessman J. Fatigue, function, and mortality in older adults. J Gerontol A Biol Sci Med Sci. 2010;65(8):887–95.CrossRefPubMed Moreh E, Jacobs JM, Stessman J. Fatigue, function, and mortality in older adults. J Gerontol A Biol Sci Med Sci. 2010;65(8):887–95.CrossRefPubMed
14.
go back to reference Stridsman C, et al. Fatigue Affects Health Status and Predicts Mortality Among Subjects with COPD: Report from the Population-Based OLIN COPD Study. COPD. 2015;12(2):199–206.CrossRefPubMed Stridsman C, et al. Fatigue Affects Health Status and Predicts Mortality Among Subjects with COPD: Report from the Population-Based OLIN COPD Study. COPD. 2015;12(2):199–206.CrossRefPubMed
15.
go back to reference Groenvold M, et al. Psychological distress and fatigue predicted recurrence and survival in primary breast cancer patients. Breast Cancer Res Treat. 2007;105(2):209–19.CrossRefPubMed Groenvold M, et al. Psychological distress and fatigue predicted recurrence and survival in primary breast cancer patients. Breast Cancer Res Treat. 2007;105(2):209–19.CrossRefPubMed
17.
go back to reference Walker EA, Katon WJ, Jemelka RP. Psychiatric disorders and medical care utilization among people in the general population who report fatigue. J Gen Intern Med. 1993;8(8):436–40.CrossRefPubMed Walker EA, Katon WJ, Jemelka RP. Psychiatric disorders and medical care utilization among people in the general population who report fatigue. J Gen Intern Med. 1993;8(8):436–40.CrossRefPubMed
18.
20.
go back to reference Lawrie SM, et al. A population-based incidence study of chronic fatigue. Psychol Med. 1997;27(2):343–53.CrossRefPubMed Lawrie SM, et al. A population-based incidence study of chronic fatigue. Psychol Med. 1997;27(2):343–53.CrossRefPubMed
21.
go back to reference Huang IC, et al. The relationships between fatigue, quality of life, and family impact among children with special health care needs. J Pediatr Psychol. 2013;38(7):722–31.CrossRefPubMedPubMedCentral Huang IC, et al. The relationships between fatigue, quality of life, and family impact among children with special health care needs. J Pediatr Psychol. 2013;38(7):722–31.CrossRefPubMedPubMedCentral
22.
go back to reference Rhee H. Relationships between physical symptoms and pubertal development. J Pediatr Health Care. 2005;19(2):95–103.PubMed Rhee H. Relationships between physical symptoms and pubertal development. J Pediatr Health Care. 2005;19(2):95–103.PubMed
23.
go back to reference Rhee H, et al. Prevalence of recurrent physical symptoms in U.S. adolescents. Pediatr Nurs. 2005;31(4):314–9. 350PubMed Rhee H, et al. Prevalence of recurrent physical symptoms in U.S. adolescents. Pediatr Nurs. 2005;31(4):314–9. 350PubMed
24.
go back to reference Varni JW, et al. The PedsQL in pediatric cancer: reliability and validity of the Pediatric Quality of Life Inventory Generic Core Scales, Multidimensional Fatigue Scale, and Cancer Module. Cancer. 2002a;94(7):2090–106.CrossRefPubMed Varni JW, et al. The PedsQL in pediatric cancer: reliability and validity of the Pediatric Quality of Life Inventory Generic Core Scales, Multidimensional Fatigue Scale, and Cancer Module. Cancer. 2002a;94(7):2090–106.CrossRefPubMed
25.
go back to reference Varni JW, Burwinkle TM, Szer IS. The PedsQL Multidimensional Fatigue Scale in pediatric rheumatology: reliability and validity. J Rheumatol. 2004;31(12):2494–500.PubMed Varni JW, Burwinkle TM, Szer IS. The PedsQL Multidimensional Fatigue Scale in pediatric rheumatology: reliability and validity. J Rheumatol. 2004;31(12):2494–500.PubMed
26.
go back to reference Varni JW, et al. The PedsQL in pediatric rheumatology: reliability, validity, and responsiveness of the Pediatric Quality of Life Inventory Generic Core Scales and Rheumatology Module. Arthritis Rheum. 2002b;46(3):714–25.CrossRefPubMed Varni JW, et al. The PedsQL in pediatric rheumatology: reliability, validity, and responsiveness of the Pediatric Quality of Life Inventory Generic Core Scales and Rheumatology Module. Arthritis Rheum. 2002b;46(3):714–25.CrossRefPubMed
27.
go back to reference Kanani A, Schellenberg R, Stark D. A pilot study of quality of life, mood, sleepiness and fatigue in patients with primary immunodeficiency receiving IVIG. Journal of Allergy and Clinical Immunology. 2007;119(1):S251.CrossRef Kanani A, Schellenberg R, Stark D. A pilot study of quality of life, mood, sleepiness and fatigue in patients with primary immunodeficiency receiving IVIG. Journal of Allergy and Clinical Immunology. 2007;119(1):S251.CrossRef
29.
go back to reference Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin North Am. 2008;28(4):779–802. viiiCrossRefPubMed Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin North Am. 2008;28(4):779–802. viiiCrossRefPubMed
31.
32.
go back to reference Abolhassani H, et al. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol. 2012;32(6):1180–92.CrossRefPubMed Abolhassani H, et al. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol. 2012;32(6):1180–92.CrossRefPubMed
33.
go back to reference Rojavin MA, Hubsch A, Lawo JP. Quantitative Evidence of Wear-Off Effect at the End of the Intravenous IgG (IVIG) Dosing Cycle in Primary Immunodeficiency. J Clin Immunol. 2016;36(3):210–9.CrossRefPubMedPubMedCentral Rojavin MA, Hubsch A, Lawo JP. Quantitative Evidence of Wear-Off Effect at the End of the Intravenous IgG (IVIG) Dosing Cycle in Primary Immunodeficiency. J Clin Immunol. 2016;36(3):210–9.CrossRefPubMedPubMedCentral
34.
go back to reference Quality., C.f.B.H.S.a. Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health. (HHS Publication No. SMA 15-4927, NSDUH Series H-50). 2015. Quality., C.f.B.H.S.a. Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health. (HHS Publication No. SMA 15-4927, NSDUH Series H-50). 2015.
35.
36.
go back to reference Parker AJ, Wessely S, Cleare AJ. The neuroendocrinology of chronic fatigue syndrome and fibromyalgia. Psychol Med. 2001;31(8):1331–45.CrossRefPubMed Parker AJ, Wessely S, Cleare AJ. The neuroendocrinology of chronic fatigue syndrome and fibromyalgia. Psychol Med. 2001;31(8):1331–45.CrossRefPubMed
37.
go back to reference Hickie I, Kirk K, Martin N. Unique genetic and environmental determinants of prolonged fatigue: a twin study. Psychol Med. 1999;29(2):259–68.CrossRefPubMed Hickie I, Kirk K, Martin N. Unique genetic and environmental determinants of prolonged fatigue: a twin study. Psychol Med. 1999;29(2):259–68.CrossRefPubMed
38.
go back to reference Harvey SB, et al. The relationship between fatigue and psychiatric disorders: evidence for the concept of neurasthenia. J Psychosom Res. 2009;66(5):445–54.CrossRefPubMedPubMedCentral Harvey SB, et al. The relationship between fatigue and psychiatric disorders: evidence for the concept of neurasthenia. J Psychosom Res. 2009;66(5):445–54.CrossRefPubMedPubMedCentral
40.
go back to reference Mahieu MA, et al. Fatigue, patient reported outcomes, and objective measurement of physical activity in systemic lupus erythematosus. Lupus. 2016. Mahieu MA, et al. Fatigue, patient reported outcomes, and objective measurement of physical activity in systemic lupus erythematosus. Lupus. 2016.
41.
42.
go back to reference Minnock P, et al. Perceptions of the Cause, Impact and Management of Persistent Fatigue in Patients with Rheumatoid Arthritis Following Tumour Necrosing Factor Inhibition Therapy. Musculoskeletal Care. 2016. Minnock P, et al. Perceptions of the Cause, Impact and Management of Persistent Fatigue in Patients with Rheumatoid Arthritis Following Tumour Necrosing Factor Inhibition Therapy. Musculoskeletal Care. 2016.
44.
45.
go back to reference van't Leven M, et al. Fatigue and chronic fatigue syndrome-like complaints in the general population. Eur J Public Health. 2010;20(3):251–7.CrossRefPubMed van't Leven M, et al. Fatigue and chronic fatigue syndrome-like complaints in the general population. Eur J Public Health. 2010;20(3):251–7.CrossRefPubMed
46.
48.
go back to reference Dinos S, et al. A systematic review of chronic fatigue, its syndromes and ethnicity: prevalence, severity, co-morbidity and coping. Int J Epidemiol. 2009;38(6):1554–70.CrossRefPubMed Dinos S, et al. A systematic review of chronic fatigue, its syndromes and ethnicity: prevalence, severity, co-morbidity and coping. Int J Epidemiol. 2009;38(6):1554–70.CrossRefPubMed
49.
go back to reference Jason LA, et al. A community-based study of chronic fatigue syndrome. Arch Intern Med. 1999;159(18):2129–37.CrossRefPubMed Jason LA, et al. A community-based study of chronic fatigue syndrome. Arch Intern Med. 1999;159(18):2129–37.CrossRefPubMed
50.
go back to reference Song S, Jason LA, Taylor RR. The Relationship Between Ethnicity and Fatigue in a Community-Based Sample. Journal of Gender, Culture and Health. 1999;4(4):255–68.CrossRef Song S, Jason LA, Taylor RR. The Relationship Between Ethnicity and Fatigue in a Community-Based Sample. Journal of Gender, Culture and Health. 1999;4(4):255–68.CrossRef
51.
go back to reference Vgontzas AN, Bixler EO, Chrousos GP. Obesity-related sleepiness and fatigue: the role of the stress system and cytokines. Ann N Y Acad Sci. 2006;1083:329–44.CrossRefPubMed Vgontzas AN, Bixler EO, Chrousos GP. Obesity-related sleepiness and fatigue: the role of the stress system and cytokines. Ann N Y Acad Sci. 2006;1083:329–44.CrossRefPubMed
54.
go back to reference Vgontzas AN, et al. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocrinol Metab. 1997;82(5):1313–6.CrossRefPubMed Vgontzas AN, et al. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocrinol Metab. 1997;82(5):1313–6.CrossRefPubMed
55.
go back to reference Lim W, et al. The association of obesity, cytokine levels, and depressive symptoms with diverse measures of fatigue in healthy subjects. Arch Intern Med. 2005;165(8):910–5.CrossRefPubMed Lim W, et al. The association of obesity, cytokine levels, and depressive symptoms with diverse measures of fatigue in healthy subjects. Arch Intern Med. 2005;165(8):910–5.CrossRefPubMed
56.
go back to reference Fukuda K, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med. 1994;121(12):953–9.CrossRefPubMed Fukuda K, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med. 1994;121(12):953–9.CrossRefPubMed
57.
go back to reference Echteld MA, et al. Multidimensional fatigue and its correlates in hospitalised advanced cancer patients. Eur J Cancer. 2007;43(6):1030–6.CrossRefPubMed Echteld MA, et al. Multidimensional fatigue and its correlates in hospitalised advanced cancer patients. Eur J Cancer. 2007;43(6):1030–6.CrossRefPubMed
58.
go back to reference Stauder MC, et al. Overall survival and self-reported fatigue in patients with esophageal cancer. Support Care Cancer. 2013;21(2):511–9.CrossRefPubMed Stauder MC, et al. Overall survival and self-reported fatigue in patients with esophageal cancer. Support Care Cancer. 2013;21(2):511–9.CrossRefPubMed
60.
go back to reference Flensner G, et al. Fatigue in relation to perceived health: people with multiple sclerosis compared with people in the general population. Scand J Caring Sci. 2008;22(3):391–400.CrossRefPubMed Flensner G, et al. Fatigue in relation to perceived health: people with multiple sclerosis compared with people in the general population. Scand J Caring Sci. 2008;22(3):391–400.CrossRefPubMed
62.
go back to reference Covinsky KE, et al. Health status versus quality of life in older patients: does the distinction matter? Am J Med. 1999;106(4):435–40.CrossRefPubMed Covinsky KE, et al. Health status versus quality of life in older patients: does the distinction matter? Am J Med. 1999;106(4):435–40.CrossRefPubMed
63.
64.
go back to reference Skeath P, et al. The nature of life-transforming changes among cancer survivors. Qual Health Res. 2013;23(9):1155–67.CrossRefPubMed Skeath P, et al. The nature of life-transforming changes among cancer survivors. Qual Health Res. 2013;23(9):1155–67.CrossRefPubMed
65.
go back to reference Masten AS, Coatsworth JD. The development of competence in favorable and unfavorable environments. Lessons from research on successful children. Am Psychol. 1998;53(2):205–20.CrossRefPubMed Masten AS, Coatsworth JD. The development of competence in favorable and unfavorable environments. Lessons from research on successful children. Am Psychol. 1998;53(2):205–20.CrossRefPubMed
Metadata
Title
Increased Incidence of Fatigue in Patients with Primary Immunodeficiency Disorders: Prevalence and Associations Within the US Immunodeficiency Network Registry
Authors
Joud Hajjar
Danielle Guffey
Charles G. Minard
Jordan S. Orange
Publication date
01-02-2017
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 2/2017
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-016-0367-1

Other articles of this Issue 2/2017

Journal of Clinical Immunology 2/2017 Go to the issue